A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial

Inclusion Criteria: * Participants with advanced, metastatic, recurrent or unresectable pheochromocytoma or paraganglioma. Pathology report or pathology slides (H\&E) confirming histological diagnosis must be available at the time of enrollment. * Must have measurable disease by RECIST v1.1. * ECOG performance status 0-2, life expectancy of at least 6 months * Adequate organ and marrow function was required (hemoglobin \>= 8.0 g/dL (5.6 mmol/L); absolute neutrophil count (ANC) \>= 1500/mm\^3; platelet count \>= 80,000/mm\^3; creatinine =\< 1.5 x ULN or creatinine clearance rate (CCr) ≥60ml/min, blood urea nitrogen (BUN) ≤2.5 × upper limit of normal (ULN); total bilirubin (TB) =\< 1.5 X ULN; aspartate transaminase (AST) and alanine aminotransferase (ALT) \<= 2.5 x ULN (if there are liver metastases, \<= 5 x ULN); albumin (ALB) ≥25 g/L; urine protein/creatinine ratio =\< 1 OR 24-hour urine protein \< 1.5 gram) * Blood pressure (BP) \< 150 mmHg (systolic) and \< 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is \< 150/90 mmHg; NOTE: all patients with secretory pheochromocytoma or paraganglioma are REQUIRED to: 1) be evaluated in consultation by a hypertension specialist with specific experience in the management of hypertension in the setting of catecholamine-secreting tumors (usually an endocrinologist, nephrologist, or a cardiologist), and in the …